Annals of Oncology Advance Access originally published online on March 12, 2007
Annals of Oncology 2007 18(5):925-930; doi:10.1093/annonc/mdm002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2007 European Society for Medical Oncology
urogenital tumors |
A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours
The Department of Medical Oncology, St Bartholomew's Hospital, London, UK
* Correspondence to: Dr J. Shamash, Department of Medical Oncology, St Bartholomew's Hospital, 7th Floor, Gloucester House, London EC1A 7BE, UK. Tel: +44-207-6017313; Fax: +44-207-6017577; E-mail: jonathan.shamash{at}bartsandthelondon.nhs.uk
Background: The outcome of patients with germ-cell tumours (GCTs), who relapse more than once or relapse with a mediastinal primary is poor. We have shown that topoisomerase 1 may be an attractive target in relapsed GCT. We investigated the role of irinotecan, paclitaxel and oxaliplatin (IPO) followed by topotecan-based high-dose therapy in responding patients, in this patient population.
Patients and methods: Twenty-eight patients with multiply relapsed gonadal and mediastinal GCT were recruited to this phase 2 study. All patients received IPO chemotherapy and 12 (43%) went on to receive high-dose therapy. The outcome of these patients was assessed using the Kaplan–Meier method with a median progression-free follow-up of 1 year.
Results: Twenty patients (71%) responded to the therapy including five complete remissions (18%), 13 (46%) marker-negative partial responses and two (7%) marker-positive partial responses. Nine (32%) patients continue to be progression free, and the median survival for the whole group currently measures 17 months. Out of 12 individuals who received subsequent high-dose therapy consolidation, seven (58%) remain progression free. The commonest grade III/IV toxicity was infection (68%) and there were no IPO-related toxic deaths; there was one death from high-dose therapy.
Conclusion: Topoisomerase I-based IPO chemotherapy that lacks etoposide is very active in multiply relapsed GCT. This data merit further investigation.
Key words: germ-cell tumour, mediastinal, phase 2, relapsed
Received for publication August 22, 2006. Revision received January 9, 2007. Accepted for publication January 10, 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Tanaka, H. Kitamura, A. Takahashi, N. Masumori, and T. Tsukamoto Long-term Outcome of Chemotherapy for Advanced Testicular and Extragonadal Germ Cell Tumors: A Single-center 27-year Experience Jpn. J. Clin. Oncol., January 1, 2010; 40(1): 73 - 78. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D M Berney Staging and classification of testicular tumours: pitfalls from macroscopy to diagnosis J. Clin. Pathol., January 1, 2008; 61(1): 20 - 24. [Abstract] [Full Text] [PDF]
|
|